Abstract:Background and objectives: T-cadherin (T-cad) is one of the adiponectin receptors abundantly expressed in the heart and blood vessels. Experimental studies show that T-cad sequesters adiponectin in cardiovascular tissues and is critical for adiponectin-mediated cardio-protection. However, there are no data connecting cardiac T-cad levels with human chronic heart failure (HF). The aim of this study was to assess whether myocardial T-cad concentration is associated with chronic HF severity and whether the T-cad … Show more
“…Their major result was that reduced cardiac T-cadherin levels might be an additional marker of chronic heart failure severity. The role of T-cadherin in the outcome prediction of patients with NIDCM has not been demonstrated in this small number of 29 patients included in the study, but the provided observations might help in future larger clinical studies [ 96 ].…”
Non-ischemic dilated cardiomyopathy encompasses a wide spectrum of myocardial disorders, characterized by left ventricular dilatation with systolic impairment and increased risk of sudden cardiac death. In spite of all the therapeutic progress that has been made in recent years, dilated cardiomyopathy continues to be an important cause of cardiac transplant, being associated with an enormous cost burden for health care systems worldwide. Predicting the prognosis of patients with dilated cardiomyopathy is essential to individualize treatment. Late gadolinium enhancement-cardiac magnetic resonance imaging, microvolt T-wave alternans, and genetic testing have emerged as powerful tools in predicting sudden cardiac death occurrence and maximizing patient’s selection. Despite all these new diagnostic modalities, additional tests to complement or replace current tools are required for better risk stratification. Therefore, biomarkers are an easy and important tool that can help to detect patients at risk of adverse cardiovascular events. Additionally, identifying potential biomarkers involved in dilated cardiomyopathy can provide us important information regarding the diagnostic, prognostic, risk stratification, and response to treatment for these patients. Many potential biomarkers have been studied in patients with dilated cardiomyopathy, but only a few have been adopted in current practice. Therefore, the aim of our review is to provide the clinicians with an update on the well-known and novel biomarkers that can be useful for risk stratification of patients with non-ischemic dilated cardiomyopathy.
“…Their major result was that reduced cardiac T-cadherin levels might be an additional marker of chronic heart failure severity. The role of T-cadherin in the outcome prediction of patients with NIDCM has not been demonstrated in this small number of 29 patients included in the study, but the provided observations might help in future larger clinical studies [ 96 ].…”
Non-ischemic dilated cardiomyopathy encompasses a wide spectrum of myocardial disorders, characterized by left ventricular dilatation with systolic impairment and increased risk of sudden cardiac death. In spite of all the therapeutic progress that has been made in recent years, dilated cardiomyopathy continues to be an important cause of cardiac transplant, being associated with an enormous cost burden for health care systems worldwide. Predicting the prognosis of patients with dilated cardiomyopathy is essential to individualize treatment. Late gadolinium enhancement-cardiac magnetic resonance imaging, microvolt T-wave alternans, and genetic testing have emerged as powerful tools in predicting sudden cardiac death occurrence and maximizing patient’s selection. Despite all these new diagnostic modalities, additional tests to complement or replace current tools are required for better risk stratification. Therefore, biomarkers are an easy and important tool that can help to detect patients at risk of adverse cardiovascular events. Additionally, identifying potential biomarkers involved in dilated cardiomyopathy can provide us important information regarding the diagnostic, prognostic, risk stratification, and response to treatment for these patients. Many potential biomarkers have been studied in patients with dilated cardiomyopathy, but only a few have been adopted in current practice. Therefore, the aim of our review is to provide the clinicians with an update on the well-known and novel biomarkers that can be useful for risk stratification of patients with non-ischemic dilated cardiomyopathy.
“… 24 Accordingly, cardiac protein expression of T-cad was downregulated in nonischemic HF adult patients with severe conditions compared to stable HF patients, suggesting for T-cad a role as an indicator of HF severity. 30 Besides studies in adult patients with HF, this is the first work that investigated the mRNA expression levels of the ADPN system in children with HF. AdipoR1, AdipoR2, and T-cad expression levels at pre-VAD were compared with their values at the moment of heart transplant.…”
Section: Discussionmentioning
confidence: 99%
“… 9 ADPN is an adipocyte-derived protein with the anti-inflammatory, anti-hypertrophic, anti-apoptotic, and anti-fibrotic role in the heart. 10 , 11 , 12 , 13 , 14 , 15 The bond of ADPN to its receptors AdipoR1, AdipoR2, and co-receptor T-cadherin (T-cad) mediates these cardioprotective effects. 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 Figure 1 Network analysis of predicted miRNA-targets.…”
“…The joining between T-cadherin and adiponectin (APN) is essential within myocardium. Reduced cardiac T-cadherin levels may deteriorate the antiinflammatory action of adipokine (10). Classical cadherins, structurally have five domains which are EC1-EC5 (starting with the N-termini of the molecule).…”
T-cadherin, a special member of cadherin family, expresses with blood circulation involving the heart i.e. CVS. Cadherin is connected with the healthy conditions of an individual and normal functioning of cardio-vascular metabolism. T-cadherin is mainly associated with blood vascular system of human. Previous studies analysed this cadherin been unexpressed within the fat storing tissues i.e. adipose tissue of peri-aortic and peri-coronary, it is present within endothelium as well as in vascularized smooth muscular cells which includes the area nearby coronary vessels and aorta. The area and site of this cadherin is attention-grabbing because it particularly related to atherosclerosis and cardiovascular disease (CVD). T-cadherin - a protein acting as the receptor for low density lipoproteins (LDL). It may act as a special biomarker for atherosclerosis. Previous studies on T-cadherin showed that it has cardio-protective role. Furthermore, research is essential to enumerate the cardio-protective function of T-cadherin. It can be an important therapeutic target in developing new medicine to decrease incident of heart disease and its complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
